Luyan Pharma Co Ltd Net Assets
Luyan Pharma Co Ltd net assets. Based on the latest financial reports, Luyan Pharma Co Ltd (002788) has net assets worth CN¥3.39 Billion CNY (≈ $496.02 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥13.34 Billion ≈ $1.95 Billion USD) and total liabilities (CN¥9.95 Billion ≈ $1.46 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See 002788 net asset quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.39 Billion |
| % of Total Assets | 25.41% |
| Annual Growth Rate | 17.32% |
| 5-Year Change | 29.84% |
| 10-Year Change | 141.19% |
| Growth Volatility | 19.82 |
Net Assets of Luyan Pharma Co Ltd (2011–2025)
Net assets of Luyan Pharma Co Ltd from 2011 to 2025. This chart illustrates how Luyan Pharma Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how fast is Luyan Pharma Co Ltd growing its equity to track the company's year-over-year net asset growth rate.
Annual Net Assets for Luyan Pharma Co Ltd (2011–2025)
The table below shows the annual net assets of Luyan Pharma Co Ltd from 2011 to 2025. For live market cap and overall valuation, see Luyan Pharma Co Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.32 Billion ≈ $486.42 Million |
+4.14% |
| 2024-12-31 | CN¥3.19 Billion ≈ $467.08 Million |
+7.22% |
| 2023-12-31 | CN¥2.98 Billion ≈ $435.62 Million |
+6.68% |
| 2022-12-31 | CN¥2.79 Billion ≈ $408.36 Million |
+9.00% |
| 2021-12-31 | CN¥2.56 Billion ≈ $374.63 Million |
+6.40% |
| 2020-12-31 | CN¥2.41 Billion ≈ $352.11 Million |
+27.45% |
| 2019-12-31 | CN¥1.89 Billion ≈ $276.28 Million |
+14.18% |
| 2018-12-31 | CN¥1.65 Billion ≈ $241.97 Million |
+5.57% |
| 2017-12-31 | CN¥1.57 Billion ≈ $229.21 Million |
+13.65% |
| 2016-12-31 | CN¥1.38 Billion ≈ $201.67 Million |
+84.74% |
| 2015-12-31 | CN¥746.00 Million ≈ $109.16 Million |
+14.89% |
| 2014-12-31 | CN¥649.30 Million ≈ $95.01 Million |
+16.39% |
| 2013-12-31 | CN¥557.87 Million ≈ $81.63 Million |
+24.48% |
| 2012-12-31 | CN¥448.15 Million ≈ $65.58 Million |
+26.27% |
| 2011-12-31 | CN¥354.91 Million ≈ $51.93 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Luyan Pharma Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1856.3% over the analyzed period, indicating profitable operations and earnings retention.
Luyan Pharma Co Ltd Net Assets Breakdown (December 2025)
Luyan Pharma Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.10 Billion | 63.43% |
| Other Components | CN¥1.21 Billion | 36.57% |
| Total Equity | CN¥3.31 Billion | 100.00% |
Luyan Pharma Co Ltd Competitors by Market Cap
The table below lists competitors of Luyan Pharma Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sage Therapeutics Inc
NASDAQ:SAGE
|
$544.94 Million |
|
Selamat Sempurna Tbk
JK:SMSM
|
$544.96 Million |
|
AmRest Holdings SE
MC:EAT
|
$545.29 Million |
|
Basler Kantonalbank
SW:BSKP
|
$545.67 Million |
|
Duzhe Publishing & Media Corp
SHG:603999
|
$544.49 Million |
|
Holike
SHG:603898
|
$544.44 Million |
|
Qingdao Weflo Valve Co Ltd
SHE:002871
|
$544.34 Million |
|
Dongguan Golden Sun Abrasives Co Ltd
SHE:300606
|
$544.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Luyan Pharma Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,162,233,658 to 3,306,986,242, a change of 144,752,584 (4.6%).
- Net income of 280,883,792 contributed positively to equity growth.
- Dividend payments of 313,959,449 reduced retained earnings.
- Other comprehensive income decreased equity by 206,523,608.
- Other factors increased equity by 384,351,849.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥280.88 Million | +8.49% |
| Dividends Paid | CN¥313.96 Million | -9.49% |
| Other Comprehensive Income | CN¥-206.52 Million | -6.25% |
| Other Changes | CN¥384.35 Million | +11.62% |
| Total Change | CN¥- | 4.58% |
Book Value vs Market Value Analysis
This analysis compares Luyan Pharma Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.13x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.04x to 1.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥1.36 | CN¥9.58 | x |
| 2012-12-31 | CN¥1.82 | CN¥9.58 | x |
| 2013-12-31 | CN¥2.27 | CN¥9.58 | x |
| 2014-12-31 | CN¥2.63 | CN¥9.58 | x |
| 2015-12-31 | CN¥3.01 | CN¥9.58 | x |
| 2016-12-31 | CN¥4.42 | CN¥9.58 | x |
| 2017-12-31 | CN¥4.51 | CN¥9.58 | x |
| 2018-12-31 | CN¥4.79 | CN¥9.58 | x |
| 2019-12-31 | CN¥5.46 | CN¥9.58 | x |
| 2020-12-31 | CN¥6.50 | CN¥9.58 | x |
| 2021-12-31 | CN¥6.44 | CN¥9.58 | x |
| 2022-12-31 | CN¥7.02 | CN¥9.58 | x |
| 2023-12-31 | CN¥7.62 | CN¥9.58 | x |
| 2024-12-31 | CN¥8.14 | CN¥9.58 | x |
| 2025-12-31 | CN¥8.51 | CN¥9.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Luyan Pharma Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.49%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.32%
- • Asset Turnover: 1.59x
- • Equity Multiplier: 4.05x
- Recent ROE (8.49%) is below the historical average (13.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 17.97% | 2.16% | 2.22x | 3.75x | CN¥28.22 Million |
| 2012 | 20.31% | 1.93% | 2.11x | 4.99x | CN¥45.94 Million |
| 2013 | 19.55% | 1.96% | 1.95x | 5.10x | CN¥52.90 Million |
| 2014 | 17.02% | 1.74% | 1.90x | 5.16x | CN¥45.10 Million |
| 2015 | 15.39% | 1.71% | 1.93x | 4.65x | CN¥39.72 Million |
| 2016 | 8.43% | 1.65% | 1.99x | 2.56x | CN¥-21.50 Million |
| 2017 | 8.86% | 1.57% | 1.62x | 3.48x | CN¥-16.79 Million |
| 2018 | 11.49% | 1.57% | 1.89x | 3.87x | CN¥23.39 Million |
| 2019 | 14.28% | 1.70% | 1.99x | 4.21x | CN¥76.72 Million |
| 2020 | 11.39% | 1.72% | 1.84x | 3.60x | CN¥32.58 Million |
| 2021 | 12.28% | 1.74% | 1.76x | 4.01x | CN¥56.70 Million |
| 2022 | 12.69% | 1.77% | 1.65x | 4.33x | CN¥73.07 Million |
| 2023 | 12.34% | 1.83% | 1.68x | 4.00x | CN¥68.90 Million |
| 2024 | 10.93% | 1.69% | 1.62x | 4.00x | CN¥29.42 Million |
| 2025 | 8.49% | 1.32% | 1.59x | 4.05x | CN¥-49.81 Million |
Industry Comparison
This section compares Luyan Pharma Co Ltd's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $2,660,748,719
- Average return on equity (ROE) among peers: 12.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Luyan Pharma Co Ltd (002788) | CN¥3.39 Billion | 17.97% | 2.94x | $544.64 Million |
| Cachet Pharmaceutical Co Ltd (002462) | $5.66 Billion | 6.26% | 1.64x | $489.61 Million |
| Yunnan Hongxiang Yixintang (002727) | $4.05 Billion | 12.87% | 0.82x | $1.11 Billion |
| Ji Yao Holding Group Co Ltd (300108) | $384.36 Million | 7.83% | 0.04x | $20.47 Million |
| ShuYu Civilian Pharmacy Corp. Ltd. (301017) | $1.91 Billion | 6.00% | 1.61x | $868.93 Million |
| Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) | $1.85 Billion | 1.44% | 2.34x | $267.51 Million |
| Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) | $2.16 Billion | 8.85% | 1.54x | $802.50 Million |
| Shanghai No1 Pharmacy Co Ltd (600833) | $186.74 Million | 13.27% | 2.88x | $316.98 Million |
| Dashenlin Pharm Grp Co Ltd (603233) | $574.85 Million | 46.19% | 3.11x | $3.07 Billion |
| Laobaixing Pharmacy (603883) | $7.17 Billion | 7.24% | 2.09x | $1.61 Billion |
About Luyan Pharma Co Ltd
Luyan Pharma Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products, and prepared slices of traditional Chinese medicine in China. The company distributes medicines, Chinese herbal medicines, medical devices, and others; and provides medical care, elderly care, and wellness services. It also operates pharmaceutical retail ch… Read more